{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T12:03:24Z","timestamp":1795262604491,"version":"4.10.3"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2210638"],"award-info":[{"award-number":["W81XWH2210638"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["101032321"],"award-info":[{"award-number":["101032321"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01 NS127846"],"award-info":[{"award-number":["R01 NS127846"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.neuropharm.2025.110599","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T23:17:45Z","timestamp":1753312665000},"page":"110599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Adenosine A2A receptor and glial glutamate transporter GLT-1 are synergistic targets to reduce brain hyperexcitability after traumatic brain injury in mice"],"prefix":"10.1016","volume":"278","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7332-3682","authenticated-orcid":false,"given":"Mariana","family":"Alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rog\u00e9rio","family":"Gerbatin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4521-6879","authenticated-orcid":false,"given":"Rebecca","family":"Kalmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6037-9364","authenticated-orcid":false,"given":"Denise","family":"Fedele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9137-0637","authenticated-orcid":false,"given":"Tobias","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7740-5781","authenticated-orcid":false,"given":"Detlev","family":"Boison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110599_bib1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clineuro.2005.09.001","article-title":"Post-traumatic epilepsy: an overview","volume":"108","author":"Agrawal","year":"2006","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.neuropharm.2025.110599_bib2","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.7150\/thno.97254","article-title":"P2X7R antagonism suppresses long-lasting brain hyperexcitability following traumatic brain injury in mice","volume":"15","author":"Alves","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.neuropharm.2025.110599_bib3","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1523\/JNEUROSCI.0089-19.2019","article-title":"Context-Specific switch from Anti- to pro-epileptogenic function of the P2Y1 receptor in experimental epilepsy","volume":"39","author":"Alves","year":"2019","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110599_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/neu.1998.15.163","article-title":"Interstitial adenosine, inosine, and hypoxanthine are increased after experimental traumatic brain injury in the rat","volume":"15","author":"Bell","year":"1998","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.neuropharm.2025.110599_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrd2997","article-title":"Key factors in the discovery and development of new antiepileptic drugs","volume":"9","author":"Bialer","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2025.110599_bib6","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0385-18.2018","article-title":"Neuronal adenosine A2A receptors are critical mediators of neurodegeneration triggered by convulsions","volume":"5","author":"Canas","year":"2018","journal-title":"eNeuro"},{"key":"10.1016\/j.neuropharm.2025.110599_bib7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11302-020-09694-2","article-title":"The belated US FDA approval of the adenosine A(2A) receptor antagonist istradefylline for treatment of Parkinson's disease","volume":"16","author":"Chen","year":"2020","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2025.110599_bib8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10072-013-1585-4","article-title":"Neuroprotective effect of ceftriaxone in a rat model of traumatic brain injury","volume":"35","author":"Cui","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110599_bib9","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3171\/2017.10.JNS17352","article-title":"Estimating the global incidence of traumatic brain injury","volume":"130","author":"Dewan","year":"2019","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.neuropharm.2025.110599_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40478-021-01165-y","article-title":"In-depth characterization of a mouse model of post-traumatic epilepsy for biomarker and drug discovery","volume":"9","author":"Di Sapia","year":"2021","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neuropharm.2025.110599_bib11","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1089\/neu.2020.7226","article-title":"In vivo detection of extracellular adenosine triphosphate in a mouse model of traumatic brain injury","volume":"38","author":"Faroqi","year":"2021","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.neuropharm.2025.110599_bib12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.pnpbp.2019.02.004","article-title":"Delayed creatine supplementation counteracts reduction of GABAergic function and protects against seizures susceptibility after traumatic brain injury in rats","volume":"92","author":"Gerbatin","year":"2019","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110599_bib13","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.bbamem.2010.12.001","article-title":"Adenosine receptors and brain diseases: neuroprotection and neurodegeneration","volume":"1808","author":"Gomes","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2025.110599_bib14","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1089\/neu.2012.2712","article-title":"Ceftriaxone treatment after traumatic brain injury restores expression of the glutamate transporter, GLT-1, reduces regional gliosis, and reduces post-traumatic seizures in the rat","volume":"30","author":"Goodrich","year":"2013","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.neuropharm.2025.110599_bib15","article-title":"Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury","volume":"8","author":"Guo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110599_bib16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/bpa.12770","article-title":"Upregulation of adenosine A2A receptor and downregulation of GLT1 is associated with neuronal cell death in Rasmussen's encephalitis","volume":"30","author":"He","year":"2020","journal-title":"Brain Pathol."},{"key":"10.1016\/j.neuropharm.2025.110599_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100230","article-title":"Ceftriaxone preserves glutamate transporters and prevents intermittent hypoxia-induced vulnerability to brain excitotoxic injury","volume":"9","author":"Jagadapillai","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110599_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/epi.13965","article-title":"Commonalities in epileptogenic processes from different acute brain insults: do they translate?","volume":"59","author":"Klein","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2025.110599_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186243","article-title":"Ceftriaxone- and N-acetylcysteine-induced brain tolerance to ischemia: influence on glutamate levels in focal cerebral ischemia","volume":"12","author":"Krzyzanowska","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110599_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/HTR.0000000000000067","article-title":"Chronic inflammation after severe traumatic brain injury: characterization and associations with outcome at 6 and 12 months postinjury","volume":"30","author":"Kumar","year":"2015","journal-title":"J. Head Trauma Rehabil."},{"key":"10.1016\/j.neuropharm.2025.110599_bib21","article-title":"Post-Traumatic, drug-resistant epilepsy and review of seizure control outcomes from blinded, randomized controlled trials of brain stimulation treatments for drug-resistant epilepsy","volume":"8","author":"Larkin","year":"2016","journal-title":"Cureus"},{"key":"10.1016\/j.neuropharm.2025.110599_bib22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12868-021-00659-8","article-title":"Ceftriaxone therapy attenuates brain trauma in rats by affecting glutamate transporters and neuroinflammation and not by its antibacterial effects","volume":"22","author":"Lim","year":"2021","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110599_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/157015909789152137","article-title":"Adenosine neuromodulation and traumatic brain injury","volume":"7","author":"Lusardi","year":"2009","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2025.110599_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071739","article-title":"Adenosine receptors as neuroinflammation modulators: role of A(1) agonists and A(2A) antagonists","volume":"9","author":"Marti Navia","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2025.110599_bib25","doi-asserted-by":"crossref","first-page":"18492","DOI":"10.1523\/JNEUROSCI.1828-13.2013","article-title":"Antagonistic interaction between adenosine A2A receptors and Na+\/K+-ATPase-alpha2 controlling glutamate uptake in astrocytes","volume":"33","author":"Matos","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110599_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.702581","article-title":"Adenosine A(2A) receptors as biomarkers of brain diseases","volume":"15","author":"Moreira-de-Sa","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110599_bib27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12974-020-01854-w","article-title":"Neuroinflammatory mechanisms of post-traumatic epilepsy","volume":"17","author":"Mukherjee","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2025.110599_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114382","article-title":"Retrograde adenosine\/A(2A) receptor signaling facilitates excitatory synaptic transmission and seizures","volume":"43","author":"Nasrallah","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2025.110599_bib29","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/nn.2341","article-title":"Adenosine A(2A) receptor mediates microglial process retraction","volume":"12","author":"Orr","year":"2009","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110599_bib30","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/805198","article-title":"Adenosine A2A receptors modulate acute injury and neuroinflammation in brain ischemia","volume":"2014","author":"Pedata","year":"2014","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.neuropharm.2025.110599_bib31","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022822","article-title":"Epileptogenesis","volume":"5","author":"Pitkanen","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.neuropharm.2025.110599_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109296","article-title":"The role of adenosine in alcohol-induced respiratory suppression","volume":"222","author":"Purnell","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110599_bib33","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1097\/00003246-200112000-00009","article-title":"Increased adenosine in cerebrospinal fluid after severe traumatic brain injury in infants and children: association with severity of injury and excitotoxicity","volume":"29","author":"Robertson","year":"2001","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.neuropharm.2025.110599_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0288363","article-title":"Delayed treatment with ceftriaxone reverses the enhanced sensitivity of TBI mice to chemically-induced seizures","volume":"18","author":"Romariz","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110599_bib35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nature03180","article-title":"Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression","volume":"433","author":"Rothstein","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2025.110599_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci9110318","article-title":"Neuroinflammation in post-traumatic epilepsy: pathophysiology and tractable therapeutic targets","volume":"9","author":"Sharma","year":"2019","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuropharm.2025.110599_bib37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/jnc.15590","article-title":"Cerebrospinal fluid purinomics as a biomarker approach to predict outcome after severe traumatic brain injury","volume":"161","author":"Strogulski","year":"2022","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2025.110599_bib38","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2025.110599_bib39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbr.2017.05.002","article-title":"Neuroprotective effects of ceftriaxone treatment on cognitive and neuronal deficits in a rat model of accelerated senescence","volume":"330","author":"Tikhonova","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2025.110599_bib40","article-title":"Adenosine A(2A) receptors control synaptic remodeling in the adult brain","volume":"12","author":"Xu","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110599_bib41","doi-asserted-by":"crossref","first-page":"821","DOI":"10.15585\/mmwr.mm6631a1","article-title":"National and State estimates of the numbers of adults and children with active epilepsy - united States, 2015","volume":"66","author":"Zack","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.neuropharm.2025.110599_bib42","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/s41598-017-02505-6","article-title":"Perivascular AQP4 dysregulation in the hippocampal CA1 area after traumatic brain injury is alleviated by adenosine A(2A) receptor inactivation","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110599_bib43","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/j.neurobiolaging.2015.04.005","article-title":"Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease","volume":"36","author":"Zumkehr","year":"2015","journal-title":"Neurobiol. Aging"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T09:27:43Z","timestamp":1779614863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825003077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":43,"alternative-id":["S0028390825003077"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110599","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenosine A2A receptor and glial glutamate transporter GLT-1 are synergistic targets to reduce brain hyperexcitability after traumatic brain injury in mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110599"}}